Cosmos Holdings Appoints Dr. Panagiotis Zoumpoulakis to Its Advisory Board - Stock News Feed

CHICAGO, IL / ACCESS CABLE / July 8, 2022 / Cosmos Holdings, Inc. (“the company”) (Nasdaq:COSM), an international pharmaceutical company with a proprietary line of nutraceuticals and a distributor of brand-name and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices, today announced the appointment of Panagiotis Zoumpoulakis, Ph.D., MBA, to its Advisory Board.

Dr. Zoumpoulakis is an established chemist with more than two decades of research experience, primarily focused on the field of nutraceuticals. He graduated from the University of Patras with postgraduate studies in Management and Administration from the Athens University of Economics and Business. Since 2020, he is Associate Professor and director of the Laboratory of Food Chemistry, Analysis and Design Processes in the Department of Food Science and Technology of the University of West Attica and Visiting Research Fellow at the Institute of Chemical Biology of the National Hellenic Research Foundation , where he has been appointed Researcher from 2008 to 2020. From 2015 to 2020, he was visiting professor at the Department of Biochemistry and Biotechnology at the University of Thessaly. From 2006 to 2017, he was a research associate at the Department of Food Technology at the Athens Institute of Technology. Previously, he served as the Secretary General of the Food Science Department of the Hellenic Chemical Association and since 2021 he has been a member of the working group on Greek nutrition of the Greek Ministry of Rural Development and Food.

Sponsored Content:

His main research interests are in the health sciences with an emphasis on drug design and bioanalysis. He has participated as coordinator, scientific director or member of research teams in more than 25 national and European research projects with competitive funding. His work is summarized in 130 original publications and revision articles in international scientific journals.

Mr. Zoumpoulakis has work experience in the field of technology transfer, while he has been actively involved in the startup ecosystem. In 2016, Dr. Zoumpoulakis co-founded Cloud PCsa biopharmaceutical research and development company, which was one of the the winning startups from Eurobank and Corallia’s Enter Grow Go contest and one of the three Greek start-ups selected to join the DMZ accelerator in Toronto, Canada.

“I am delighted to join the Cosmos advisory board,” said Dr. Panagiotis Zoumpoulakis. “In particular, I share Cosmos’ passion for researching and developing beneficial products that address major health conditions. I look forward to helping Cosmos advance new products that improve patients’ lives.”

“We are very pleased to welcome Dr. Zoumpoulakis to our advisory board, which follows our recent strategic partnership with Cloudpharm PC to launch a research project focused on microbiome-based obesity management,” said Greg Siokas, Director executive of Cosmos Holdings. . “We believe that his extensive experience in biopharmaceutical research will prove invaluable as we move forward with this project, as well as future projects targeting the gastrointestinal microbiome. We look forward to having Dr. Zoumpoulakis join our team during this crucial time.”

Sponsored Content: is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping

About Cosmos Holdings, Inc.

Cosmos Holdings Inc. (Nasdaq:COSM) is an international pharmaceutical company with a proprietary line of nutraceuticals and a distributor of brand-name and generic pharmaceuticals, nutraceuticals, over-the-counter drugs and medical devices through an extensive distribution network established in the European Union. The Company identifies, acquires, develops and markets products that improve the lives and outcomes of patients. Cosmos has developed a global distribution platform and is currently expanding across Europe, Asia and North America. Cosmos Holdings has offices and distribution centers in Thessaloniki, Greece, Athens, Greece, and Harlow, UK. More information is available at Y

Forward-looking statements

Except for the historical information contained in this press release, the matters described in this document may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act. Stock Exchange of 1934. , as amended. Statements preceded, followed or otherwise include the words “believes”, “expects”, “anticipates”, “intends”, “projects”, “estimates”, “plans” and similar expressions or future tense or conditional verbs such as “will”, “should”, “would”, “could” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein, for a variety of reasons beyond the Company’s control, including, but not limited to, the Company’s ability to obtain sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and economy in general, and the Company’s ability to successfully develop and commercialize its products and technologies patented. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained in this document. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available on the SEC’s website ( The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

Crescendo Communications, LLC
Phone: 212-671-1020
Email: [email protected]

FONT: Cosmos Holdings, Inc.

See source version at access

Source link

Leave a Reply

Your email address will not be published.